Print  Close

Evaluation of trends of neoadjuvant therapy for Breast Cancer using Joinpoint

Abstract Number:

3763 

Submission Type:

Contributed Abstract 

Contributed Abstract Type:

Poster 

Participants:

Hui Zhao (1)

Institutions:

(1) University of Texas-MD Anderson Cancer Center, N/A

First Author:

Hui Zhao  
University of Texas-MD Anderson Cancer Center

Presenting Author:

Hui Zhao  
University of Texas-MD Anderson Cancer Center

Abstract Text:

Neoadjuvant therapy is on the rise to treat HER2-Positive breast cancer. However, there is no study evaluates the trend of neoadjuvant in the past decade.
In this study, we included breast cancer patients ≥18 years diagnosed with stage I to III HER2-positive breast cancer who received chemotherapy, and surgery from the Surveillance, Epidemiology, and End Results Program from 2010 to 2020. Joinpoint models were used to assess trends in neoadjuvant treatment and association of patients' characteristics and neoadjuvant treatment was evaluated by generalized estimating equations.
A total of 59,965 women with median age of 56 years, 60.9% were White, 14.5% were Hispanic, 11.9% were Asian, 11.6% were Black, and 1% were other or unknow race ethnicity. Neoadjuvant chemotherapy was increased from 20.1% to 46.1% between 2010-2020 (p-value <.001). Neoadjuvant increased the most in stage I patients with the average annual percent change (AAPC) of 22 with 95% confidence interval (CI) of (18-26.2) followed by 10.1 (8.5-11.8), and 4.4 (2.0-7.0) for stage II and III respectively. Neoadjuvant therapy for HER2-Positive EBC increases and its survival effects need to be evaluated.

Keywords:

trend|joinpoint|breast cancer| | |

Sponsors:

Section on Statistics in Epidemiology

Tracks:

Electronic Health Records

Can this be considered for alternate subtype?

Yes

Are you interested in volunteering to serve as a session chair?

Yes

I have read and understand that JSM participants must abide by the Participant Guidelines.

Yes

I understand that JSM participants must register and pay the appropriate registration fee by June 1, 2024. The registration fee is non-refundable.

I understand